Startseite>>Amylin, amide, human TFA

Amylin, amide, human TFA

Katalog-Nr.GC72109

Amylin, amide, human TFA, ein 37-Aminosäurepolypeptid, ist ein mit Insulin cosekretiertes Pankreashormon, das einzigartige Rollen im Stoffwechsel und der Glukosehomöostase spielt.

Products are for research use only. Not for human use. We do not sell to patients.

Amylin, amide, human TFA Chemische Struktur

Größe Preis Lagerbestand Menge
500 µg
216,00 $
Auf Lager
1 mg
347,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.

MCF-7 cells endogenously express human amylin receptor CTR1 and CTR2. Stimulation of the receptor with Amylin, amide, human results in the production of cAMP. Amylin, amide, human (0.001 nM-1000 μM) results in an EC50 of 35.2±7.5 nM[1].

Amylin, amide, human (400 μg peptide /kg body weight) is injected by subcutaneous route in separated groups of swiss male mice. A typical PK curve for the free amylin is observed, with a half-time of 23 min[1].

References:
[1]. Sisnande T, et al. Monoconjugation of Human Amylin with Methylpolyethyleneglycol. PLoS One. 2015 Oct 8;10(10):e0138803.

Bewertungen

Review for Amylin, amide, human TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amylin, amide, human TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.